Metlife INC

MetLife, Inc. announced the declaration of quarterly and semi-annual dividends for its various series of preferred stock.

MetLife Inc. announced robust second-quarter 2026 results, showcasing a 15% increase in adjusted earnings and a 20% rise in adjusted earnings per share, driven by favorable underwriting and volume growth.

MetLife, Inc. has disclosed preliminary variable investment income for the quarter ended June 30, 2026, estimating it to be between $220 million and $270 million pre-tax.

MetLife, Inc. announced robust first-quarter 2026 results, with net income up 30% and adjusted earnings up 18%, driven by strong performance across its business segments.

MetLife estimates first-quarter variable investment income between $475 million and $525 million, tracking ahead of its annual guidance pace.

MetLife, Inc. confirmed its first quarter 2026 dividend of $0.31501229 per share on its Series A preferred stock, payable March 16, 2026.

MetLife Inc. announced robust financial results for the second quarter of 2026, showcasing significant year-over-year growth in adjusted earnings and premiums across key business segments.

MetLife reports a significant increase in net income and adjusted earnings for Q1 2026, bolstered by strategic reorganization and strong segment performance.

MetLife reports a decline in GAAP net income for Q3 and 9M 2025, primarily due to market volatility, while adjusted earnings show growth for the quarter.

MetLife, Inc. reported a decrease in net income and adjusted earnings for the second quarter and first half of 2025, influenced by market factors and underwriting adjustments, while pursuing strategic acquisitions and reinsurance transactions.

MetLife's Q1 2025 results show increased net income and the authorization of an additional $3.0 billion for common stock repurchases.

MetLife's Q3 2024 results show a significant increase in net income, driven by favorable investment and derivative gains, despite some headwinds from market volatility and actuarial adjustments.

MetLife, Inc. announced increased adjusted earnings and revenue growth in 2025, driven by strategic reorganization and key segment performance, despite a decline in GAAP net income.

MetLife's 2024 10-K filing highlights the company's execution of its New Frontier strategy aimed at accelerating growth and delivering attractive returns in a dynamic economic landscape.

MetLife's 10-K filing details the company's registered securities, dividend policies, corporate governance, and preferred stock terms.

Christian Stephane Mumenthaler, a Director at MetLife Inc., acquired 587 shares of common stock on June 16, 2026, as part of the company's non-management director compensation plan.

MetLife, Inc. director William E. Kennard acquired 587 shares of common stock through a director compensation plan.

MetLife, Inc. Director Jeh C. Johnson acquired 587 shares of common stock through a director compensation plan, increasing his beneficial ownership.

MetLife, Inc. director Diana McKenzie acquired company common stock as part of her compensation, with the transaction occurring on June 16, 2026.

MetLife, Inc. director Laura J. Hay acquired 587 shares of common stock through a director compensation plan, increasing her beneficial ownership.

MetLife, Inc. director Robert Glenn Hubbard acquired 1,016 shares of common stock through a deferred compensation plan, increasing his beneficial ownership.

MetLife, Inc. has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.

MetLife unveils its 'New Frontier' five-year strategy, building on the success of 'Next Horizon,' while refreshing its board with the addition of Christian Mumenthaler and preparing for upcoming director retirements.

MetLife, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pertaining to Section 14(a) of the Securities Exchange Act of 1934.

MetLife's proxy statement highlights the company's resilience in navigating market uncertainties and its focus on strategic execution, including the appointment of a new board member and ongoing board refreshment.

MetLife Inc. has submitted its Form 13F for the quarter ending March 31, 2026, detailing its institutional investment holdings across various ETFs.

MetLife Inc. filed its Q4 2025 13F-HR report, revealing $12.15 million in equity holdings across six ETFs.

MetLife Inc. filed its Q3 2025 13F-HR report, revealing $11.13 million in equity holdings across six ETFs, primarily focused on international and broad market indices.

MetLife Inc. has filed its Form 13F-HR, revealing its equity holdings for the quarter ended June 30, 2025, totaling over $10.39 million across six distinct positions.

MetLife Inc. reports its Q1 2025 investment holdings, totaling $9,675,997 across six positions, as per its Form 13F filing.

MetLife Inc.'s latest 13F filing reveals its equity holdings as of December 31, 2024, showcasing investments in various iShares and SPDR ETFs.

MetLife's Board of Directors has amended its Schedule 13D filing to report beneficial ownership of 102,098,469 shares, representing 16.1% of the company's common stock, held through the MetLife Policyholder Trust.

The MetLife Board of Directors filed a Schedule 13D disclosing beneficial ownership of 103,885,196 shares held in the MetLife Policyholder Trust.

MetLife's Board of Directors filed an amendment to Schedule 13D, reporting beneficial ownership of 105.37 million shares held by the MetLife Policyholder Trust, representing 16.2% of outstanding common stock.

MetLife's Board of Directors has reported beneficial ownership of 106.5 million common shares, representing 16.17% of the company's outstanding stock, held through the MetLife Policyholder Trust.

MetLife's Board of Directors reports beneficial ownership of 108.24 million shares held by the MetLife Policyholder Trust, representing 16.28% of common stock.

MetLife, Inc.'s Board of Directors has filed an amendment to its Schedule 13D, reporting beneficial ownership of 109,404,080 shares, or 16.3%, of the company's Common Stock held by the MetLife Policyholder Trust.

Vanguard Capital Management has disclosed beneficial ownership of 41,496,623 shares, representing 6.36% of MetLife Inc.'s common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for MetLife Inc., reporting 0% beneficial ownership following an internal realignment.

The Vanguard Group reported an 11.01% beneficial ownership stake in MetLife Inc., holding over 72.5 million shares as of December 31, 2025.

The Vanguard Group updated its beneficial ownership in MetLife Inc., reporting a 9.73% stake as of September 30, 2025.